VivoSeq
Other

Lateral Canthal Lines

0

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Lateral Canthal Lines is an early-stage landscape with 0 programs across 4 companies. The most active players are Revance Therapeutics, Inc., Eirion Therapeutics Inc., Ipsen.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Revance Therapeutics, Inc.

0 programs

PreclinicalE

Eirion Therapeutics Inc.

0 programs

PreclinicalIpsen logo

Ipsen

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

26

clinical trials

Completed26 · 100%

Clinical Trials

Trial Activity

26 trials

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
Completed·RRevance Therapeutics, Inc.·Phase 3·NCT02580370·450 enrolled
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Completed·RRevance Therapeutics, Inc.·Phase 2·NCT00907387·72 enrolled
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Completed·RRevance Therapeutics, Inc.·Phase 2·NCT00888914·60 enrolled
MT10109L in the Treatment of Lateral Canthal Lines
Completed·MMedy-Tox·Phase 3·NCT03785145·235 enrolled
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
Completed·RRevance Therapeutics, Inc.·Phase 2·NCT01064518·90 enrolled
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Completed·RRevance Therapeutics, Inc.·Phase 2·NCT00968942·36 enrolled
Treatment of Moderate to Severe Lateral Canthal Lines
Completed·GGalderma R&D·Phase 3·NCT04249687·303 enrolled
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
Completed·GGalderma R&D·Phase 3·NCT05148000·25 enrolled
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
Completed·EEirion Therapeutics Inc.·Phase 2·NCT04985916·280 enrolled
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
Completed·MMedy-Tox·Phase 3·NCT04157686·957 enrolled
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Completed·RRevance Therapeutics, Inc.·Phase 2·NCT00884234·30 enrolled
Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)
Completed·Ipsen logoIpsen·Phase 2·NCT00247559·221 enrolled
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
Completed·GGalderma R&D·Phase 3·NCT04247074·413 enrolled
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
Completed·RRevance Therapeutics, Inc.·Phase 2·NCT01124565·40 enrolled
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
Completed·MMedy-Tox·Phase 3·NCT03721016·415 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)